MSL. Summit. Best Practices. 2 ND EUROPEAN Medical & Scientific. Register Now

Transcription

1 Bringing Maximum Value to the KOL, Company, and Industry 2 ND EUROPEAN Medical & Scientific ADVISOR and Best Practices MSL Summit O C T O B E R, K E M P I N S K I H O T E L B R I S T O L B E R L I N, G E R M A N Y Featured Sessions Include: NEW TECHNOLOGIES FOR MSLS TO ENGAGE WITH DOCTORS SUSANNE HARZER, Scientific Affairs Manager, Cardiovascular, SANOFI THE PRODUCT LIFECYCLE: WHAT ROLE DOES THE MEDICAL SCIENCE MANAGER (MSM) HAVE THROUGHOUT THE PRODUCT LIFECYCLE? LUDOVIC HACOPIAN, Director, Field Medical Operations Director, Europe, BRISTOL-MYERS SQUIBB Featuring an Exceptional Faculty from These Industry Leaders: Ozan Batigun, Head of Medical Department, TEVA Nurhayat Buladi, Medical Scientific Liaison, MSD Ian Forn Palacin, Regional Medical Manager/MSL, GRUNENTHAL Tobias Gantner, Head of Market Access, BAYER David Gillen, Head of International Medical Affairs, GILEAD MEASURING SUCCESS WITH KOLS: BUILDING RELATIONSHIPS AND MANAGING INTERACTIONS MIEKE VANDENBERGHE, MD MBA, Scientific Programmes & Communications Manager, Europe and Central Asia, MEDTRONIC PANEL DISCUSSION: HOW IS THE RELATIONSHIP BETWEEN MSLS AND COMMERCIAL OPERATIONS EVOLVING? OZAN BATIGUN, Head of Medical Department, TEVA SERDAR OZTURK, Medical Affairs Manager, NOVO NORDISK JONAS HYLTON, Associate Director, Medical Science Liaisons, CEPHALON DAVID GILLEN, Head of International Medical Affairs, GILEAD MARIA JESSA, Medical manager, CHC, SANOFI Co-located with ExL Pharma s 4 th European Investigator-Initiated Trials Conference: For Maximum Learning and Networking Opportunities Register Now Amy Gomez, Medical Liaison Operations Consultant, ELI LILLY Ludovic Hacopian, Director, Field Medical Operations Director, Europe, BRISTOL-MYERS SQUIBB Susanne Harzer, Scientific Affairs Manager, Cardiovascular, SANOFI Jonas Hylton, Associate Director, Medical Science Liaisons, CEPHALON Maria Jessa, Medical Manager, CHC, SANOFI Serdar Ozturk, Medical Affairs Manager, NOVO NORDISK Chris Sugg, National Scientific Director - Managed Markets, NOVARTIS ONCOLOGY Lincoln Tsang, Partner, ARNOLD & PORTER LLP Marc Van Melckenbeke, Senior Global Director Medical Communications & Coordination, Global Medical Affairs, UCB Mieke Vandenberghe, MD MBA, Scientific Programmes & Communications Manager, Europe and Central Asia, MEDTRONIC

2 Register Now Dear Colleague, Who Should Attend? I m writing to introduce to you ExL Pharma s 2 nd European Medical & Scientific Advisor and MSL Best Practices Summit. Last year s event featured insightful presentations on defining the role of the MSL, off-license information, and performance evaluation. But the MSL role in Europe is continually evolving, and it is essential for Medical Affairs professionals to keep current with how to best communicate internally and with the outside community. After the tremendous success of last year s event, we re excited to assemble a diverse, high-level faculty to discuss the most pressing issues in communicating accurate medical information to key stakeholders. Our international speaker staff consists of leaders from pharmaceutical companies. MSL functions vary from country to country as much as they do company to company. Attendees at ExL Pharma s 2nd European Medical & Scientific Advisor and MSL Best Practices Summit will have the opportunity to hear best practices and network with peers in a single location for two days. I look forward to seeing you in Berlin this Fall. Sincerely, Dave Hoffman Conference Director dhoffman@exlpharma.com Matt Millman Division Head, Program Development mmillman@exlpharma.com From Pharmaceutical, Biotech, and Medical Device companies: Medical Science Liaisons (MSL, MLs) Medical and Scientific Advisors Medical Managers and Scientists Medical Development Advisors Regional Scientific Services Medical and Scientific Affairs Medical Communications Clinical Trial Liaisons Clinical Research Medical Education Clinical/Outcomes Liaisons Clinical Investigators KOL Development Business Intelligence Regulatory Affairs Marketing SPONSORSHIP AND EXHIBIT OPPORTUNITIES Do you want to spread the word about your organization s solutions and services to potential clients who attend this event? Take advantage of the opportunity to exhibit, present an educational session, host a networking event, or distribute promotional items to attendees. ExL works closely with you to customize a package that suits all of your needs. To learn more about these opportunities, contact Eric Morrin, Business Development, by calling or by ing emorrin@exlpharma.com. This event is also of interest to: Software Companies Market Research Companies Medical Communications Consulting Agencies Staffing Agencies and Recruiters EXL PHARMACEUTICAL TRAINING DIVISION Looking for a pharmaceutical training program that offers hands-on experience and are designed to fit your specific corporate needs? Contact Michael Goldberg at or mgoldberg@exlpharma.com for more details. HOTEL INFO KEMPINSKI HOTEL BRISTOL BERLIN KURFÜRSTENDAMM BERLIN, GERMANY PHONE: Located directly on the famous Kurfürstendamm boulevard, the grande dame amongst the Berlin hotels is unmistakably eye-catching with its striking semi-circular swung facade. Well-known figures and business travelers alike from all over the world appreciate the comfort, service, cuisine and cultural highlights in the Kempinski Hotel Bristol. Room Reservations: If you require overnight accommodations, please contact the hotel and request the group rate for "ExL Pharma October" meetingwe encourage conference participants to make reservations by Wednesday 21st September 2011 with our designated venue as our discounted room rates are limited.

3 DAY ONE THURSDAY, 20 OCTOBER, :00 Registration and Continental Breakfast 9:00 PRE-CONFERENCE WORKSHOP: HOW TO DEVELOP INTERNAL GUIDELINES & PROCESSES TO ENSURE COMPLIANCE OF MSL PROGRAMS Objectives Why compliance matters Consequences of non-compliance Identifying key areas of risk and developing internal guidelines Training and monitoring to ensure compliance Strategies for creating global or regional standards for the role A voting system will be used. Workshop Leaders: MARC VAN MELCKENBEKE, Senior Global Director, Medical Communications & Coordination, Global Medical Affairs, UCB AMY GOMEZ, Medical Liaison Operations Consultant, ELI LILLY 10:30 Refreshment and Networking Break 12:00 Workshop Concludes; Lunch for Workshop Attendees PRE-CONFERENCE WORKSHOP MAIN CONFERENCE BEGINS DAY ONE 12:00 Registration for Main Conference Attendees 1:00 CHAIRPERSON S INTRODUCTION CHRIS SUGG, National Scientific Director - Managed Markets, NOVARTIS ONCOLOGY 1:15 THE EVOLVING ROLE OF MSLS IN THE EUROPEAN MARKETPLACE What is the ideal MSL structure local versus regional? Medical Advisors, Scientific Advisors, and MSLs as medical spokespeople Applying skill sets based on how medicine is delivered in a given country SERDAR OZTURK, Medical Affairs Manager, NOVO NORDISK 2:00 PERFORMANCE METRICS: WHAT IS THE APPROPRIATE MEASURE OF MSL PERFORMANCE? How can medical departments demonstrate the value of their MSL activities Measuring frequency and reach versus assessing the quality of lasting relationships and company access Qualitative measurement surveys Demonstrating value beyond health and efficacy JONAS HYLTON, Associate Director, Medical Science Liaisons, CEPHALON 2:45 Networking and Refreshment Break 3:15 MSL PERFORMANCE FROM DIFFERENT PERSPECTIVES: HOW MAY EXPECTATIONS DIFFER BETWEEN DEPARTMENTS? What are the differences between MSLs and sales reps? What is the relationship between medical managers and MSLs? What do marketing/sales, market access, regulatory and clinical trial operations, and safety/pv expect from MSL? What are the expectations from key opinion leaders and associations? How do MSLs influence reimbursement committees or other payers? NURHAYAT BULADI, Medical Scientific Liaison, MSD 4:00 NEW TECHNOLOGIES FOR MSLS TO ENGAGE WITH DOCTORS Webex video conferencing Doctors using the internet for research How does social media facilitate or complicate MSLs relationships? Using mobile technology for more accessibility SUSANNE HARZER, Scientific Affairs Manager, Cardiovascular, SANOFI 4:45 ROUNDTABLE DISCUSSIONS: AUDIENCE MEMBERS SPLIT INTO SMALLER GROUPS FOR INTERACTIVE DISCUSSIONS OF KEY ISSUES. ATTENDEES WILL ALSO HAVE THE OPTION OF PARTICIPATING IN ROUNDTABLES WITH THE 4TH EUROPEAN INVESTIGATOR INITIATED TRIALS SUMMIT. Working in the rare disease space with niche or orphan drugs CHRIS SUGG, National Scientific Director - Managed Markets, NOVARTIS ONCOLOGY Tapping into research networks SUSANNE HARZER, Scientific Affairs Manager, Cardiovascular, SANOFI Should Companies Think About Outsourcing MSLs? LUDOVIC HACOPIAN, Director, Field Medical Operations Europe, European Field Medical Centre of Excellence, BRISTOL-MYERS SQUIBB Investing MSLs in emerging markets MARIA JESSA, MEDICAL MANAGER, CHC, SANOFI What is the impact of biosimilars on the MSL function? For more information about our roundtable options, visit 5:15 Close of Day One

4 DAY TWO FRIDAY, 21 OCTOBER, :00 Continental Breakfast 9:00 CHAIRPERSON S RECAP OF DAY ONE MARC VAN MELCKENBEKE, Senior Global Director, Medical Communications & Coordination, Global Medical Affairs, UCB 9:15 PANEL DISCUSSION: HOW IS THE RELATIONSHIP BETWEEN MSLS AND COMMERCIAL OPERATIONS EVOLVING? A discussion of the purpose and law of some European regulations How does sales/marketing view the MSL role? Is it appropriate to measure any kind of commercial ROI for MSL activities? How to create an efficient working environment with sales and marketing Moderator: OZAN BATIGUN, Head of Medical Department, TEVA Panelists: SERDAR OZTURK, Medical Affairs Manager, NOVO NORDISK JONAS HYLTON, Associate Director, Medical Science Liaisons, CEPHALON DAVID GILLEN, Head of International Medical Affairs, GILEAD MARIA JESSA, Medical manager, CHC, SANOFI 10:00 OPPORTUNITIES FOR MSLS IN PRE AND POST LAUNCH REIMBURSEMENT STRATEGIES Evaluating the reimbursement outlook is critical to a products success and helps bring products to market of more value. This section will look at strategies where MSLs can contribute while the relationships with payers and providers are changing Key considerations when conducting a reimbursement analysis. Reducing variability of care. Thinking beyond clinical guidelines Advantages to building global market access teams CHRIS SUGG, National Scientific Director - Managed Markets, NOVARTIS ONCOLOGY 10:45 Networking and Refreshment Break 11:15 GRUNENTHAL CASE STUDY: SUCCESSFULLY CREATING A ROLE FOR MSLS IN THE SPANISH MARKET Determining the function MSLs will play in your company and the industry Establishing credibility among the rest of the company regarding MSLs Setting benchmarks to measure success for the MSL program IAN FORN PALACIN, Regional Medical Manager/MSL, GRUNENTHAL 12:00 THE PRODUCT LIFECYCLE: WHAT ROLE DOES THE MEDICAL SCIENCE MANAGER (MSM) HAVE THROUGHOUT THE PRODUCT LIFECYCLE? What is the product lifecycle and what are the associated field medical activities? What are the different approaches to lifecycle flexing? What are the implications of lifecycle flexing? LUDOVIC HACOPIAN, Director, Field Medical Operations Director, Europe, BRISTOL-MYERS SQUIBB 12:45 Luncheon 1:45 KOL LANDSCAPE: HOW IS THE MSL/KOL RELATIONSHIP EVOLVING? How will disclosure of payments affect the KOL industry? Identifying and approaching KOLs Customer or business partner; expectations of both parties Evaluating KOL performance OZAN BATIGUN, Head of Medical Department, TEVA 2:45 MEASURING SUCCESS WITH KOLS: BUILDING RELATIONSHIPS AND MANAGING INTERACTIONS Gathering field insights through responsive inquiry to guide future interactions and ensure working in tandem with the sales team Identifying key performance indicators (KPIs) and clarifying goals for the KOL relationship How to track MSL contacts for KOLs Clarifying the goals of the KOLs and understanding how they align with your company s goals MIEKE VANDENBERGHE, MD MBA, Scientific Programmes & Communications Manager, Europe and Central Asia, MEDTRONIC 3:30 Networking and Refreshment Break 4:00 MARKET ACCESS CASE STUDY: THE ROLE OF MSL DRIVEN ADVOCACY IN A MANAGED MARKET: A GERMAN PERSPECTIVE The mechanics of centrally managed markets and the new challenges for the pharmaceutical industry The scientific foundation of market success: Where science meets sales is market access Why and how market access and MSLs have to work closely together to assure product success Communicating the dossier approved value message on all levels: MSLs and market access strategies TOBIAS GANTNER, Head of Market Access, BAYER 4:45 REGULATIONS AND THE MSL ROLE: MAXIMALLY COMMUNICATING ESSENTIAL INFORMATION WITHOUT CROSSING ANY LINES Preparing to give information when it s solicited anticipating needs without influencing Mastering effective communication skills without crossing the line into sales How Does the NIH s Health and Social Care Bill in the UK effect MSL Interactions? LINCOLN TSANG, Partner, ARNOLD & PORTER LLP 5:30 Conference Concludes Register Now

5 REGISTRATION FEES FOR ATTENDING EXL S 2 ND EUROPEAN Medical & Scientific ADVISOR and MSL EARLY BIRD PRICING Register by Friday, 16, September, 2011 to Take Advantage of Early-Bird Pricing: Conference + Workshop 1695 Conference Only 1495 Best Practices Summit MEDIA PARTNERS PM 36O THE FULL SPECTRUM OF PRODUCT MANAGEMENT STANDARD PRICING Register After Friday, 16 September, 2011 Conference + Workshop 1895 Conference Only 1695 ONSITE PRICING Conference + Workshop 2095 Conference Only 1895 Make checks payable to ExL Events, Inc. and write code P1132 on your check. You may also use Visa, MasterCard, Discover or American Express. Payments must be received in full prior to the commencement of the conference. DELEGATE PROFILE FROM PREVIOUS EUROPEAN MSL BEST PRACTICES CONFERENCE Medical/Scientific Affairs Medical Science Liaison Other Driving innovation Through Leading Education ExL Pharma, a division of ExL Events, Inc., is an industry leader in developing innovative, educational conferences that serve the pharmaceutical and allied healthcare communities in the United States, Europe and Latin America. Behind our diverse pharmaceutical event portfolio, our experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality events designed to exceed the dynamic informational and networking needs of specific audiences and working groups. We organize over 60+ conferences per year that facilitate the exchange of critical information between industry executives and suppliers who support their scientific and commercial goals. Our pharmaceutical conferences are the preferred resource for industry professionals seeking important information and networking opportunities with a clear delineation between content and commercialism. Our conferences have been a leading resource for industry executives to meet and network over key industry issues and to explore innovative products and services for over 6 years. We look forward to serving your informational and networking needs at a future industry event! Register Now

6 Four Ways to Register PRIORITY CODE: Mail: ExL Events, Inc th Ave, Ste 310 New York, NY Phone: Online: Bringing Maximum Value to the KOL, Company, and Industry 2 ND EUROPEAN Medical & Scientific ADVISOR and Best Practices MSL ATTENTION MAILROOM: If undeliverable to addressee, please forward to Medical Science Liaison, Medical Affairs Director, Scientific/Medical Advisor Summit O C T O B E R, K E M P I N S K I H O T E L B R I S T O L B E R L I N, G E R M A N Y Hotel Information: ExL Register Pharma me is pleased for... to offer our delegates a limited number of hotel rooms at a discounted rate until Sept. 21, Please contact the hotel directly and mention "ExL Pharma October" conference to receive this rate. CONFERENCE VENUE: KEMPINSKI HOTEL BRISTOL BERLIN ADDRESS: KURFÜRSTENDAMM BERLIN, GERMANY RESERVATIONS: Group Discount Program: offers cannot be combined, early bird rates do not apply Yes! Name: Register me for CONFERENCE CODE: P1132 Conference and Workshop Conference only Registration Fo rm EARLY BIRD PRICING Before 16, September, Title: STANDARD PRICING After 16 September, Save 25% Per Person when Registering Four For every three simultaneous registrations from your company, you will receive a fourth complimentary registration to the program (must register 4 at one time). This is a savings of 25% per person. Company: Dept.: Save 15% per person when Registering Three Can only send three? You can still save 15% off of every registration. To find out more on how you can take advantage of these group discounts, please call Cancellations: If you need to cancel your registration for an upcoming ExL conference, please note the following policies derived from the Start Date of the event: Four weeks or more: A full refund (minus a 95 processing fee), or a voucher to another ExL event valid for two years from the voucher issue date. Four weeks or Less: : A voucher to another ExL event valid for two years from the voucher issue date. To receive a refund or voucher, please fax your request to Please Note: Conference registrations may be transferred to other colleagues in the event you are unable to attend. There will be an administrative charge of 300 to substitute, exchange and/or replace attendance badges with a colleague occurring within five business days of any ExL conference. Please notify ExL Pharma, info@exlpharma.com, prior to the event with the name and contact information of the replacement attendee. Please Note: Speakers and agenda are subject to change without notice. In the event of a speaker cancellation, every effort to find a suitable replacement will be made. *In the event of a cancellation or postponement ExL Events, Inc. will not be liable and/or responsible for any individual or group expenses related to said conference. Address: City: State: Zip: Telephone: Please contact me: I m interested in marketing opportunities at this event Fax: I wish to receive updates on ExL Pharma s upcoming events Payment Type: MASTERCARD VISA DISCOVER AMEX Card Number: Name on Card: Signature: CHECK (Make checks payable to ExL Events, Inc.) Exp. Date: